Ronopterin - vasopharm BIOTECH
Alternative Names: VAS-203Latest Information Update: 06 Jun 2021
Price :
$50 *
At a glance
- Originator vasopharm BIOTECH
- Class Neuroprotectants; Pteridines; Small molecules
- Mechanism of Action Nitric oxide synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Brain injuries
Most Recent Events
- 03 Jun 2021 Efficacy data from a phase III NOSTRA-III trial in Brain injury released by vasopharm BIOTECH
- 15 Apr 2021 Ronopterin is still in phase III trial for Brain injuries in Austria, Spain, Germany, France and United Kingdom (IV) (vasopharm BIOTECH website, April 2021)
- 01 Jul 2020 Vasopharm completes the phase III NOSTRA trial in Brain injuries in Germany, Spain, Austria, UK, France